Get the Stockscreener App
1.70
3.66%
0.06
Pre-market:
1.74
0.04
+2.35%
Pacific Biosciences Of California Inc stock is traded at $1.70, with a volume of 8.18M.
It is up +3.66% in the last 24 hours and down -13.71% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.64
Open:
$1.66
24h Volume:
8.18M
Relative Volume:
0.85
Market Cap:
$465.57M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.1333
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
-8.11%
1M Performance:
-13.71%
6M Performance:
+2.41%
1Y Performance:
-74.20%
1-Day Range:
$1.62
$1.73
1-Week Range:
$1.59
$2.01
52-Week Range:
$1.16
$7.50
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.70 | 465.57M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped - MSN
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics - MSN
RNA Transcriptome Profiling Tests Market Expands at 14.5% CAGR, Surpassing US$ 37 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
Chromosome-level genome assembly of the pine wood nematode carrier Arhopalus unicolor - Nature.com
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now - MSN
PacBio announces preliminary Q4 revenue of $39.2M - MSN
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownShould You Sell? - MarketBeat
PacBio Stock May Gain Following the Collaborated Launch of GutID - MSN
PACB Stock Declines Despite Promising HiFi Sequencing Findings - Yahoo Finance
Don't Ignore The Insider Selling In Pacific Biosciences of California - Simply Wall St
Selling Pacific Biosciences of California Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Bought by Barclays PLC - MarketBeat
PacBio reports drop in annual revenue, launches new products By Investing.com - Investing.com Canada
PacBio reports drop in annual revenue, launches new products - Investing.com India
PacBio's HiFi Sequencing Achieves 93% Success Rate in Breakthrough Rare Disease Study - StockTitan
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue - Quantisnow
Pacific Biosciences COO Mark Van Oene sells shares for $69,979 - Investing.com India
Whole genome sequencing, assembly and annotation of the Southern Ground Hornbill – Bucorvus leadbeateri - Nature.com
Pacific Biosciences COO Mark Van Oene sells shares for $69,979 By Investing.com - Investing.com Canada
Insider Selling: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Sells 34,405 Shares of Stock - MarketBeat
Pacbio and Intus Bio Collaborate for Launch of Gutid - Marketscreener.com
PacBio Launches GutID: Revolutionary At-Home Microbiome Test Using HiFi Sequencing - StockTitan
Pacific Biosciences of California (NASDAQ:PACB) Upgraded to Sell at StockNews.com - MarketBeat
PacBio delivers first Vega systems to Berry Genomics By Investing.com - Investing.com Nigeria
PacBio delivers first Vega systems to Berry Genomics - Investing.com
PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets - Quantisnow
Why the Market Dipped But Pacific Biosciences of California (PACB) Gained Today - MSN
PacBio Delivers First Vega DNA Sequencers to Berry Genomics in Major China Expansion - StockTitan
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 7.2%What's Next? - MarketBeat
Pacific Biosciences of California Sees Unusually Large Options Volume (NASDAQ:PACB) - MarketBeat
PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Barclays PLC Boosts Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Chromosome-level genome assembly of Triplophysa bombifrons using PacBio HiFi sequencing and Hi-C technologies - Nature.com
Why Is Pacific Biosciences of California, Inc. (PACB) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $2.95 Consensus Target Price from Analysts - MarketBeat
State Street Corp Boosts Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Third Generation Sequencing Market Key Players Analysis - openPR
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
China Neurogenomics Market Research 2024-2031, Profiles of Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, MGI Tech, Agilent, Revvity, Qiagen, Pacific Biosciences, Danaher, Oxford NanoporeResearchAndMarkets.com - WICZ
Fmr LLC Has $694,000 Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):